PD-L1 CPS As a Biomarker for Patient Selection for Immunotherapy in Advanced Esophagogastric Adenocarcinoma

By Cedars Sinai FEATURING Jun Gong
By Cedars Sinai FEATURING Jun Gong
260 views
May 13, 2022
Comments 0
Login to view comments. Click here to Login